Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Non-Current Liabilities (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Total Non-Current Liabilities for 13 consecutive years, with $195.5 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 64.53% to $195.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $195.5 million through Dec 2025, down 64.53% year-over-year, with the annual reading at $195.5 million for FY2025, 64.53% down from the prior year.
  • Total Non-Current Liabilities hit $195.5 million in Q4 2025 for Coherus Oncology, down from $411.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $842.7 million in Q1 2024 to a low of $195.5 million in Q4 2025.
  • Historically, Total Non-Current Liabilities has averaged $584.4 million across 5 years, with a median of $581.7 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 82.71% in 2021 and later plummeted 64.53% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $580.9 million in 2021, then grew by 5.84% to $614.8 million in 2022, then skyrocketed by 31.83% to $810.5 million in 2023, then tumbled by 31.99% to $551.2 million in 2024, then plummeted by 64.53% to $195.5 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CHRS at $195.5 million in Q4 2025, $411.2 million in Q3 2025, and $318.1 million in Q2 2025.